Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 10/20 | 0.56 |
| ▸ | CCNH | P51946 | 10/20 | 0.56 |
| ▸ | MNAT1 | P51948 | 10/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 3/20 | 0.45 |
| ▸ | CDK9 | P50750 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18313073 | 0.94 | CDK7 (0.51) | CDK7CCNHMNAT1CDK5CDK5R1 | |
| SCHEMBL21654891 | 0.90 | CSNK2A1 (0.59) | CDK7CCNHMNAT1CSNK2A1CDK2 | |
| SCHEMBL20550095 | 0.88 | CSNK2A1 (0.62) | CDK7CCNHMNAT1CDK5CDK5R1 | |
| SCHEMBL18122693 | 0.88 | CSNK2A1 (0.62) | CDK7CCNHMNAT1CDK5CDK5R1 | |
| SCHEMBL20549689 | 0.86 | CDK2 (0.54) | CDK7CCNHMNAT1CDK5CDK5R1 | |
| SCHEMBL20288862 | 0.86 | CDK2 (0.54) | CDK7CCNHMNAT1CDK5CDK5R1 | |
| SCHEMBL18313623 | 0.83 | CSNK2A1 (0.56) | CDK7CCNHMNAT1CDK5CDK5R1 | |
| SCHEMBL18072919 | 0.82 | CDK7 (0.65) | CDK7CCNHMNAT1CDK2CDK9 | |
| SCHEMBL20549657 | 0.81 | CDK2 (0.51) | CDK7CCNHMNAT1CDK5CDK5R1 | |
| SCHEMBL18313283 | 0.81 | CDK2 (0.51) | CDK7CCNHMNAT1CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550121-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550121-B2 | Inhibitors of cyclin-dependent kinases | CDK3, CDK13, CDK1 | CDK7 12/4885CCNH 46/4885MNAT1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.